Pharmacokinetics of temafloxacin in humans after multiple oral doses
- PMID:1318680
- PMCID: PMC188445
- DOI: 10.1128/AAC.36.2.378
Pharmacokinetics of temafloxacin in humans after multiple oral doses
Abstract
The multiple-dose pharmacokinetics and tolerance of temafloxacin, a new fluoroquinolone antibacterial agent, were evaluated in healthy volunteers. Temafloxacin was found to be well tolerated when administered orally every 12 h for 7 days at doses of 100, 200, 300, 400, 600, and 800 mg. Steady-state maximum and minimum concentrations in plasma were proportional to dose, averaging slightly over 1.0 and 0.5 microgram/ml/100 mg administered. Analyses of variance found no significant differences among the dosage groups in total apparent clearances (CLT/F), renal clearances (CLR), or nonrenal clearances, which averaged 197, 119, and 78 ml/min, respectively. The half-life increased slightly with dose, averaging 8.4 h overall. The extent of absorption of temafloxacin was quite reproducible, with day-to-day intrasubject variability in minima averaging under 10%. Renal glomerular filtration of unbound drug was the dominant elimination process; however, tubular secretion and reabsorption also appear to occur. Secretion was estimated to account for about 12% of CLT/F during a regimen of 600 mg every 12 h. CLR was relatively constant for urine flow rates above 1 ml/min, but reabsorption appeared to occur under low-flow conditions, resulting in day-versus-night differences in CLR. Intersubject variability in CLT/F over the eightfold range in dosage was only 20%, and 60% of this variance was accounted for by differences in body surface area (or lean body mass), concentration in plasma, and urine flow rate. Overall, it appears that the pharmacokinetics of temafloxacin are essentially linear, reproducible within a subject, and predictable among subjects.
Similar articles
- Pharmacokinetics of temafloxacin after multiple oral administration.Granneman GR.Granneman GR.Clin Pharmacokinet. 1992;22 Suppl 1:14-23. doi: 10.2165/00003088-199200221-00005.Clin Pharmacokinet. 1992.PMID:1319867Review.
- Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.Granneman GR, Braeckman R, Kraut J, Shupien S, Craft JC.Granneman GR, et al.Antimicrob Agents Chemother. 1991 Nov;35(11):2345-51. doi: 10.1128/AAC.35.11.2345.Antimicrob Agents Chemother. 1991.PMID:1666497Free PMC article.
- Pharmacokinetics of temafloxacin in humans after single oral doses.Granneman GR, Carpentier P, Morrison PJ, Pernet AG.Granneman GR, et al.Antimicrob Agents Chemother. 1991 Mar;35(3):436-41. doi: 10.1128/AAC.35.3.436.Antimicrob Agents Chemother. 1991.PMID:2039194Free PMC article.Clinical Trial.
- Pharmacokinetics of temafloxacin in patients with liver impairment.Granneman GR, Mahr G, Locke C, Nickel P, Kirch W, Fabian W, Kinzig M, Naber KG, Sörgel F.Granneman GR, et al.Clin Pharmacokinet. 1992;22 Suppl 1:24-32. doi: 10.2165/00003088-199200221-00006.Clin Pharmacokinet. 1992.PMID:1319868Clinical Trial.
- Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review.Sorgel F, Naber KG, Kinzig M, Mahr G, Muth P.Sorgel F, et al.Am J Med. 1991 Dec 30;91(6A):51S-66S. doi: 10.1016/0002-9343(91)90312-l.Am J Med. 1991.PMID:1662896Review.
Cited by
- The effect of food on the bioavailability of temafloxacin. A review of 3 studies.Granneman GR, Mukherjee D.Granneman GR, et al.Clin Pharmacokinet. 1992;22 Suppl 1:48-56. doi: 10.2165/00003088-199200221-00009.Clin Pharmacokinet. 1992.PMID:1319871
- Pharmacokinetics of temafloxacin after multiple oral administration.Granneman GR.Granneman GR.Clin Pharmacokinet. 1992;22 Suppl 1:14-23. doi: 10.2165/00003088-199200221-00005.Clin Pharmacokinet. 1992.PMID:1319867Review.
- Hepatobiliary elimination of temafloxacin.Sörgel F, Granneman GR, Mahr G, Kujath P, Fabian W, Nickel P.Sörgel F, et al.Clin Pharmacokinet. 1992;22 Suppl 1:33-42. doi: 10.2165/00003088-199200221-00007.Clin Pharmacokinet. 1992.PMID:1319869
- Effect of antacid medication on the pharmacokinetics of temafloxacin.Granneman GR, Stephan U, Birner B, Sörgel F, Mukherjee D.Granneman GR, et al.Clin Pharmacokinet. 1992;22 Suppl 1:83-9. doi: 10.2165/00003088-199200221-00014.Clin Pharmacokinet. 1992.PMID:1319875Clinical Trial.
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources